Medifast, Inc.(MED)Earnings, Financials & Key RatiosMedifast, Inc. (MED) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's core business model is facing structural obsolescence as evidenced by a 34.3% year-over-year revenue decline and a shift to negative free cash flow margins of -1.1%.
Medifast, Inc. (MED) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Medifast, Inc. (MED) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.19vs $0.55+65.5% | $76Mvs $69M+9.9% |
| Q1 2026 | Feb 17, 2026 | $0.55vs $0.76+27.6% | $75Mvs $71M+5.2% |
| Q4 2025 | Nov 3, 2025 | $0.21vs $0.01-2000.0% | $89Mvs $71M+25.2% |
| Q3 2025 | Aug 4, 2025 | $0.04vs $0.30+113.3% | $106Mvs $94M+12.5% |
Recent stock market news and headlines for Medifast, Inc. (MED)
The heavy selling pressure might have exhausted for Medifast (MED) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Key metrics vs top competitors for Medifast, Inc. (MED)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.89 | $121.09M | -6.41 | -35.96% | -4.84% | -9.13% | 0.16% | |
| $36.17 | $7.94B | 70.92 | 59% | -0.56% | -2.48% | — | |
| $5.17 | $251.01M | 1.63 | -14.26% | 3.78% | 6.84% | — | |
| $22.38 | $413.2M | 38.59 | 8.28% | 0.96% | 1.51% | — | |
| $22.54 | $1.61B | 26.21 | 8.48% | 5.05% | 12.84% | — | |
| $15.78 | $157.78M | 0.15 | -9.58% | 155.5% | 334.45% | — |
Medifast, Inc. (MED) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Medifast, Inc. (MED) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 4, 2026·SEC
Mar 20, 2026·SEC
Feb 17, 2026·SEC
Get notified when MED posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Medifast, Inc. (MED) stock FAQ — growth, dividends, profitability & financials explained
Medifast, Inc. (MED) reported $346.1M in revenue for fiscal year 2025. This represents a 1997% increase from $16.5M in 1996.
Medifast, Inc. (MED) saw revenue decline by 36.0% over the past year.
Medifast, Inc. (MED) reported a net loss of $20.0M for fiscal year 2025.
Yes, Medifast, Inc. (MED) pays a dividend with a yield of 0.16%. This makes it attractive for income-focused investors.
Medifast, Inc. (MED) has a return on equity (ROE) of -9.1%. Negative ROE indicates the company is unprofitable.
Medifast, Inc. (MED) had negative free cash flow of $1.5M in fiscal year 2025, likely due to heavy capital investments.
